Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, May 1996, 351-354, Vol 3, No. 3
K Oishi, H Tanaka, F Sonoda, S Borann, K Ahmed, Y Utsunomiya, K Watanabe, T Nagatake, M Vaneechoutte, G Verschraegen and K Matsumoto
A hybrid cell line producing a monoclonal antibody (MAb) against Moraxella
(Branhamella) catarrhalis lipopolysaccharide (LPS) was established. The
specificity of the MAb 1B12 to purified rough LPSs from six strains of M.
catarrhalis was ascertained by enzyme-linked immunosorbent assay (ELISA),
competitive-inhibition ELISA, and immunoblotting. MAb 1B12 bound to live
bacterial cells and culture supernatants from a total of 34 strains of M.
catarrhalis, including 12 strains with different LPS serotypes. No
cross-reactions with smooth and rough LPSs from selected enterobacterial
and nonenterobacterial strains, with other respiratory pathogens, or with
Neisseria species were observed. These data suggest that MAb 1B12
recognizes a common epitope of M. catarrhalis LPS which differs from
serotype determinants.
Copyright © 1996 by the American Society for Microbiology. All rights reserved.
A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides
Department of Internal Medicine, Nagasaki University, Japan.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |